Stacey Coen appointed Senior Vice President and Chief Business Officer at ImmunoGen
ImmunoGen have appointed Stacey Coen as their new Senior Vice President and Chief Business Officer.
She joins the company from Editas Medicine, where she served as Vice President, Business Development and was responsible for business strategies, transactions and alliance management.
Mark Enyedy, ImmunoGen’s President and Chief Executive Officer, said: “We are excited to welcome Stacy to the ImmunoGen leadership team as mirvetuximab soravtansine moves through registration studies and our early-stage pipeline continues to advance. Stacy is a proven business leader with broad corporate strategy and business development expertise, and will play an important role in our organization as we continue to execute against our strategy, explore new opportunities for our pipeline, and seek to bring mirvetuximab to patients as quickly as possible.”
Prior to her role at Editas, Coen served in multiple roles at Genzyme Corporation, now Sanofi Genzyme, including Vice President, Head of Rare Disease Business Development and Licensing, and Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis. She is also on the Board of Trustees of the Huntington’s Disease Society of America, and is a member of MassBio and the Alliance for Regenerative Medicine.
In terms of education, she received a BS in Finance and Economics from the University of Massachusettes and an MBA from the Darden Graduate School of Business at the University of Virginia.
On her appointment, Coen said: “I am delighted to join ImmunoGen as the Company works to bring its first product to market and advance a portfolio of novel ADCs. I look forward to working with the talented team at ImmunoGen and contributing to the goal of delivering more good days to people living with cancer.”